N@N

Somaxon Pharmaceuticals Announces Acceptance of Phase 3 Clinical Trial Data for Publication in Sleep and Sleep Medicine

^{Published on 2010-07-21 13:15:41 - Market Wire}
 

SAN DIEGO--([ BUSINESS WIRE ])--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the companya™s product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.

"These articles detail Phase 3 clinical data demonstrating that doxepin showed significant improvements compared to placebo on multiple efficacy endpoints relating to insomnia, with a favorable safety and tolerability profile"

The article entitled aEfficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia,a is currently available on-line and is expected to be published in Sleep in the next two months.

This Phase 3 clinical trial enrolled 240 elderly subjects, and efficacy assessments evaluated both objective polysomnography (PSG) and subjective measures of sleep. Subjective efficacy assessments were made both in the sleep laboratory and on an outpatient basis. Safety and efficacy were evaluated over a twelve week period, which the company believes represents the longest clinical trial reported to date for insomnia that evaluated efficacy in both the sleep laboratory and outpatient settings.

Both doses of Silenor achieved statistical significance for objective measures of sleep maintenance in the sleep laboratory setting, including the primary endpoint of Wake After Sleep Onset (WASO), and for subjective measures of sleep maintenance and sleep onset in the outpatient setting. Effects at week twelve were generally statistically significant and similar to or improved from those observed at week one.

With respect to safety, the incidence of adverse events in this trial was comparable to placebo. There were no statistically significant differences relative to placebo in next day residual effects, no amnesia or memory impairment was reported in the Silenor treated group, and there were no differences compared to placebo in weight gain.

Somaxona™s other article that has been accepted for publication, entitled aEfficacy and Safety of Doxepin 6 mg in a Model of Transient Insomnia,a is expected to be published in Sleep Medicine in the next three months.

This Phase 3 clinical trial enrolled 565 adults in a sleep laboratory setting using a phase-advance, first night assessment model of induced transient insomnia. Efficacy assessments evaluated both objective PSG and subjective measures of sleep. The results demonstrated that Silenor achieved statistical significance for objective and subjective measures of sleep onset, including for the primary endpoint of Latency to Persistent Sleep (LPS), and sleep maintenance.

The incidence of adverse events was comparable to placebo. There were no reports of amnesia, memory impairment or anticholinergic effects, and there were no clinically meaningful effects on measures of next day impairment.

The articles represent a subset of the data from Somaxona™s completed clinical development program underlying the approved New Drug Application (NDA) for Silenor for the treatment of insomnia characterized by difficulties with sleep maintenance.

aThese articles detail Phase 3 clinical data demonstrating that doxepin showed significant improvements compared to placebo on multiple efficacy endpoints relating to insomnia, with a favorable safety and tolerability profile,a said Thomas Roth, Ph.D., chief, division head, Sleep Disorders & Research Center, Henry Ford Hospital and an author on both articles. aThis data, together with the remainder of the data from Somaxona™s clinical program, suggests that Silenor is an important option available for the management of insomnia patients.a

aThe acceptance of these articles for publication is another milestone in our commercialization plan for Silenor as we look forward to an October launch,a said Richard W. Pascoe, Somaxona™s president and chief executive officer. aThe articles, which describe Silenora™s safety and efficacy in the elderly and adult insomnia populations, together with others that we hope to have published in the future, will serve to educate healthcare providers on the comprehensive data that resulted from our Silenor clinical program.a

About Silenor®

Silenor is a low-dose (3 mg, 6 mg) oral tablet formulation of doxepin that is patent protected for use in insomnia. The Silenor NDA was approved in March 2010 for the treatment of insomnia characterized by difficulties with sleep maintenance. The NDA included all of the data from the companya™s development program, including data from Somaxona™s clinical trial program that evaluated 1,017 subjects exposed to Silenor from 12 studies.

Important Safety Information

A doctor should be consulted if insomnia worsens or is not better within 7 to 10 days. This may mean that there is another condition causing the sleep problem.

Patients should be sure that they are able to devote 7 to 8 hours to sleep before being active again. Silenor should be taken within 30 minutes of bedtime. Patients should not take Silenor with alcohol or with other medicines that can cause drowsiness. Silenor should not be taken with or within two weeks after taking a monoamine oxidase inhibitor (MAOI). Patients should not take Silenor if they have untreated narrow angle glaucoma, if they have severe urinary retention, if they have severe sleep apnea or if they are allergic to any of the ingredients in Silenor. Until patients know how they will react to Silenor, they should not drive or operate machinery at night after taking Silenor, and they should be careful in performing such activities during the day following taking Silenor. Before taking Silenor, patients should tell their doctors if they have a history of depression, mental illness or suicidal thoughts. Patients should call their doctors right away if after taking Silenor they walk, drive, eat or engage in other activities while asleep. Drowsiness was the most common adverse event observed in clinical trials.

For more information, please see the complete Prescribing Information, including the Medication Guide, at [ www.silenor.com ] or [ www.somaxon.com ].

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxona™s product Silenor® (doxepin) has been approved by the FDA for the treatment of insomnia characterized by difficulties with sleep maintenance.

For more information, please visit the companya™s web site at [ www.somaxon.com ].

Somaxon cautions readers that statements included in this press release that are not a description of historical facts are forward-looking statements.For example, statements regarding the publication of articles regarding Silenor clinical data in peer-reviewed scientific journals, the use of clinical data to educate healthcare providers and the timing of Somaxona™s commercial launch are forward-looking statements.The inclusion of forward-looking statements should not be regarded as a representation by Somaxon that any of its plans will be achieved.Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Somaxona™s business, including, without limitation, Somaxona™s ability to successfully commercialize Silenor; inadequate therapeutic efficacy or unexpected adverse side effects relating to Silenor that could delay or prevent commercialization, or that could result in recalls or product liability claims; the ability of Somaxon to achieve market acceptance of Silenor; Somaxona™s reliance on a third party, Publicis, for critical aspects of the commercial sales process for Silenor; the potential to enter into and the terms of any commercial partnership or other strategic transaction relating to Silenor; the ability of Somaxon to ensure adequate and continued supply of Silenor to successfully launch commercial sales or meet anticipated market demand; the scope, validity and duration of patent protection and other intellectual property rights for Silenor; whether the approved label for Silenor is sufficiently consistent with such patent protection to provide exclusivity for Silenor; Somaxona™s ability to operate its business without infringing the intellectual property rights of others; the market potential for insomnia treatments, and Somaxona™s ability to compete within that market; other difficulties or delays in development, testing, manufacturing and marketing of Silenor; the timing and results of post-approval regulatory requirements for Silenor, and the FDAa™s agreement with Somaxona™s interpretation of such results; Somaxona™s ability to raise sufficient capital to fund its operations, and the impact of financing activities on the level of its stock price; and other risks detailed in Somaxona™s prior press releases as well as in its periodic filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.All forward-looking statements are qualified in their entirety by this cautionary statement, and Somaxon undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.